Clinical trials: Stage I Skin Cancer
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
This phase I trial tests the safety, side effects, and best dose of ASTX727 when given in combination with a usual approach of treatment with paclitaxel and pembrolizumab in patients with triple-negative breast cancer that has…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
- Trial name
- NCT05673200
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 10 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Timing of Menstrual Cycle and Surgery in Treating Premenopausal Women With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: The timing of breast cancer surgery within the menstrual cycle may affect outcome. It is not yet known if treatment is more effective during the initial or final phase of the menstrual cycle.
- Trial name
- NCT00005079
- Testing
- conventional surgery
- Where
- 2 sites in United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Anxiety Disorder, Breast Cancer
Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Acupuncture may help relieve muscle and bone pain caused by aromatase inhibitor therapy, such as letrozole, exemestane, and anastrozole.
- Conditions
- Anxiety Disorder, Breast Cancer, Depression, Fatigue
- Trial name
- NCT00641303
- Testing
- acupuncture therapy
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- University of Maryland, Baltimore
Metastatic Melanoma
Taxotere/Temodar/Cisplatin Study in Melanoma Patients
Primary Objective: 1. To determine the maximum tolerated dose of chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in patients with metastatic melanoma. Secondary Objectives: 1.
- Trial name
- NCT00527761
- Testing
- Cisplatin, Docetaxel, Temodar
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Chemotherapy
A Pilot Study to Evaluate the Safety and Activities of EW02 in Reducing Neutropenia Caused by Chemotherapy
Study Hypothesis: EW02 is a polysaccharide-enriched crude extract from black soybean (BS). BS has been used extensively by the Chinese as food or traditional Chinese medicine for hundreds of years.
- Conditions
- Breast Cancer, Chemotherapy, Neutropenia
- Trial name
- NCT00555516
- Testing
- EW02
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Tri-Service General Hospital (TSGH)
HER2-positive Breast Cancer, Male Breast Cancer
Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer
This randomized phase I/II trial studies the side effects and best dose of rintatolimod when given together with vaccine therapy and sargramostim (GM-CSF) to see how well it works in treating patients with stage II-IV human…
- Conditions
- HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT01355393
- Testing
- HER-2/neu peptide vaccine, sargramostim, rintatolimod
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Melanoma, Colon Cancer
Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
Background: Exome sequencing can identify certain gene mutations in a person's tumor. This can then be used to create cancer treatments.
- Conditions
- Melanoma, Colon Cancer, Gastrointestinal Cancer, Genitourinary Cancer
- Trial name
- NCT03480152
- Testing
- National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Triple Negative Breast Cancer, Breast Neoplasms
Vaccination of Triple Negative Breast Cancer Patients
The purpose of this study is to evaluate a new investigational cancer vaccine, P10s-PADRE in combination with standard neoadjuvant chemotherapy and surgery in patients with clinical stage I, II or III triple negative breast…
- Trial name
- NCT02938442
- Testing
- P10s-PADRE with MONTANIDE™ ISA 51 VG, Doxorubicin, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of Arkansas
Breast Cancer, Stage I Breast Cancer
Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer
This phase II trial is studying how well vorinostat works in treating women who are undergoing surgery for newly diagnosed stage I, stage II, or stage III breast cancer.
- Conditions
- Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
- Trial name
- NCT00262834
- Testing
- vorinostat, conventional surgery
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study
The purpose of this study is to compare the changes in a proliferation biomarker in subjects receiving Anastrozole or Anastrozole/ZD1839 combination.
- Trial name
- NCT00255463
- Testing
- Anastrazole, Gefitinib
- Where
- 34 sites in Czechia, France and 5 more
- Volunteers
- 185 people
- Sponsor
- AstraZeneca
Triple Negative Breast Cancer
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
This is a Phase I/II Trial Evaluating the Safety and Efficacy of ProAgio, an anti- αvβ3 Integrin Cytotoxin, in Combination with Gemcitabine in Patients with Metastatic Triple Negative Breast Cancer
- Trial name
- NCT06460298
- Testing
- ProAgio Dose Levels (DL) 1,2,3,4, ProAgio Dose Expansion
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- ProDa BioTech, LLC
Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2.
- Conditions
- Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT04180371
- Testing
- BT5528, Nivolumab
- Where
- 28 sites in United States, Belgium and 3 more
- Volunteers
- 288 people
- Sponsor
- BicycleTx Limited
Breast Cancer
Effect of Tamoxifen on Breast Density in Premenopausal Women With Breast Cancer or High Risk for Breast Cancer
RATIONALE: High estrogen levels may be associated with dense breast tissue and an increased risk of developing breast cancer. Tamoxifen may be effective in reducing breast density by decreasing estrogen levels.
- Trial name
- NCT00086749
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Breast Cancer Detection, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Validation of the Oncoliq Test for the Early Detection of Breast Cancer.
Cancer continues to be one of the most significant public health issues worldwide. Thanks to early detection, the mortality rate of certain types of cancer has decreased significantly.
- Conditions
- Breast Cancer Detection, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer Female, Breast Cancer - Ductal Carcinoma in Situ (DCIS)
- Trial name
- NCT07331506
- Testing
- Peripheral blood draw
- Where
- Argentina
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Oncoliq US Inc
Breast Cancer, Brain Metastases
Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer
The purpose of this research study is to determine the safety of combining lapatinib plus radiation in patients with breast cancer that has spread to the brain.
- Trial name
- NCT00470847
- Testing
- Lapatinib, Whole Brain Radiation, Herceptin
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Nancy Lin, MD
Breast Cancer, Breast Cancer Female
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC
This research was done to evaluate the safety and effectiveness of a drug currently known as Azenosertib (ZN-C3) in combination with the drugs carboplatin and pembrolizumab in metastatic triple-negative breast cancer.
- Conditions
- Breast Cancer, Breast Cancer Female, Triple Negative Breast Cancer, Hormone Receptor Negative Malignant Tumor Breast Triple
- Trial name
- NCT06351332
- Testing
- Azenosertib, Carboplatin, Pembrolizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Filipa Lynce, MD
Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
This phase II trial tests how well neratinib prior to the primary treatment (neoadjuvant) works in treating patients with stage I-III HER2 mutated lobular breast cancers.
- Conditions
- Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer, Anatomic Stage III Breast Cancer, Invasive Breast Lobular Carcinoma
- Trial name
- NCT05919108
- Testing
- Endocrine Therapy, Biopsy of breast, Neratinib
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Cancer
PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer
Non-randomized, open label, multicentric translational research study in women with untreated invasive breast carcinoma eligible for primary surgery (Stage I-IIIA).
- Trial name
- PAMELA (NCT01973660)
- Testing
- Lapatinib, Trastuzumab, Endocrine Therapy
- Where
- 22 sites in Spain
- Volunteers
- 151 people
- Sponsor
- SOLTI Breast Cancer Research Group
Breast Neoplasms, Breast Diseases
Leflunomide in Previously Treated Metastatic Triple Negative Cancers
Triple negative breast cancer (TNBC) represents about 15% of breast cancers and is characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and HER-2 non-amplification.
- Conditions
- Breast Neoplasms, Breast Diseases, Metastatic Triple Negative Breast Cancer
- Trial name
- NCT03709446
- Testing
- Leflunomide
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Joseph Sparano
Breast Cancer, Breast Neoplasms
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors.
- Conditions
- Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer
- Trial name
- NCT00600496
- Testing
- AZD6244, Dacarbazine, Erlotinib
- Where
- 4 sites in United States
- Volunteers
- 140 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.